<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-26556" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pancrelipase Therapy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Venkatesh</surname>
            <given-names>Priyanka</given-names>
          </name>
          <aff>Rajiv Gandhi University ,</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kasi</surname>
            <given-names>Anup</given-names>
          </name>
          <aff>University of Kansas</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Priyanka Venkatesh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anup Kasi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-26556.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Pancrelipase, a combination of lipase, protease, and amylase, has benefited patients with exocrine pancreatic insufficiency. The FDA-approved conditions that are associated with pancreatic insufficiency that may require supplementation with pancrelipase include chronic pancreatitis, obstructive pancreatic tumors, post-procedure loss of pancreatic tissue or ductal occlusion, insufficient mixing of chyme with pancreatic enzymes because of rapid gastric emptying, small bowel resection with inadequate secretion of cholecystokinin-pancreozymin and secretin, and lymph node dissection leading to decreased pancreatic stimulation. Also approved are genetic disorders including cystic fibrosis, Schwachman Diamond syndrome, hereditary hemochromatosis, Zollinger-Ellison syndrome, celiac disease, and Crohn disease. There are also non-FDA-approved indications as well. This activity outlines the indications, mechanism of action, methods of administration, significant adverse effects, contraindications, monitoring, and toxicity of pancrelipase so providers can direct patient therapy to optimal outcomes in conditions where pancrelipase has benefit.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of pancrelipase.</p></list-item><list-item><p>Summarize the approved and off-label indications for pancrelipase.</p></list-item><list-item><p>Review the adverse event profile of pancrelipase.</p></list-item><list-item><p>Explain the importance of improving care coordination among the interprofessional team to enhance the delivery of care for patients who can benefit from therapy with pancrelipase.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26556&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26556">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-26556.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Pancrelipase, a combination of lipase, protease, and amylase, has been shown to benefit patients with exocrine pancreatic insufficiency.<xref ref-type="bibr" rid="article-26556.r1">[1]</xref></p>
        <p>The different conditions that are associated with pancreatic insufficiency that may require supplementation with pancrelipase are:</p>
        <p>
<bold>FDA-Approved</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Chronic pancreatitis: Structural damage involving the pancreatic ducts and acinar cells, which result from a prolonged inflammatory reaction in the pancreas, is the most common cause of insufficiency<xref ref-type="bibr" rid="article-26556.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Tumors: Obstruction of the pancreatic duct by a tumor in the pancreas/ampulla leads to atrophy, causing enzyme deficiency<xref ref-type="bibr" rid="article-26556.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Post-surgery:
<list list-type="bullet"><list-item><p>Pancreatic resection: Loss of glandular tissue or duct occlusion post-procedure<xref ref-type="bibr" rid="article-26556.r4">[4]</xref></p></list-item><list-item><p>Gastric resection: Insufficient mixing of chyme with pancreatic enzymes because of rapid gastric emptying<xref ref-type="bibr" rid="article-26556.r5">[5]</xref></p></list-item><list-item><p>Small bowel resection: Inadequate secretion of cholecystokinin-pancreozymin and secretin</p></list-item><list-item><p>Lymph node dissection: Postcibal asynchrony and decreased pancreatic stimulation</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Genetic disorders:
<list list-type="bullet"><list-item><p>Cystic fibrosis: An autosomal recessive disorder resulting from mutations in both copies of the gene for cystic fibrosis transmembrane conductance regulator (CTFR) on chromosome 7. The resultant protein regulates chloride and sodium transport across the endothelial cell membranes in exocrine glands. The major implication of this condition is the blockage of pancreatic ducts from the inspissated secretions resulting thereof<xref ref-type="bibr" rid="article-26556.r6">[6]</xref></p></list-item><list-item><p>Schwachman Diamond syndrome: An autosomal recessive disorder that presents in infancy. The usual presentation includes skeletal abnormalities, neutropenia, bone marrow dysfunction, and exocrine pancreatic insufficiency.</p></list-item><list-item><p>Hereditary hemochromatosis: An autosomal recessive disorder resulting from mutations in the <italic toggle="yes">HFE</italic> gene coding for hepcidin, transferrin, hemojuvelin, and ferroportin results in the increased absorption and deposition of iron in the body. Deposition of iron in the pancreas leads to reduced glandular function.</p></list-item><list-item><p>Zollinger-Ellison syndrome: A rare condition resulting from the development of gastrinomas or gastrin-secreting tumors in the stomach and duodenum. About 30% of cases occur as a part of MEN1 syndrome, which has an autosomal dominant inheritance pattern. Increased gastrin production leads to the suppression of pancreatic enzymes.</p></list-item><list-item><p>Celiac disease: An autoimmune condition inherited in either an autosomal dominant or recessive manner that may result in a decreased CCK secretion which secondarily results in reduced pancreatic secretion</p></list-item><list-item><p>Crohn's disease: An autoimmune condition that may cause the production of antibodies directed against the pancreas, which interferes which enzyme production</p></list-item><list-item><p>Autoimmune pancreatitis: IgG4-related disease that eventually progresses to exocrine pancreas insufficiency</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Non-FDA Approved</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Enteral feeding tube occlusion:&#x000a0;Administration of a pancreatic enzyme and sodium bicarbonate solution to blocked feeding tube effectively relieved the obstruction. The efficacy was further improved by applying the solution closer to the clogged&#x000a0;area using a catheter.<xref ref-type="bibr" rid="article-26556.r7">[7]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26556.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The alkaline pH of the duodenum activates the components of pancrelipase, which then helps&#x000a0;with digestion.<xref ref-type="bibr" rid="article-26556.r8">[8]</xref><xref ref-type="bibr" rid="article-26556.r9">[9]</xref></p>
        <p>
<bold>Lipase</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Pancreatic lipase catalyzes the hydrolysis of triglycerides to monoglycerides, fatty acids, and glycerol.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Colipase&#x000a0;anchors the lipase to the lipid-water membrane of the micelle producing a change in the structure of that surface.&#x000a0;The hydrophobic active site is thus exposed to the binding of the triglycerides and the subsequent interaction with the catalytic triad. There is hydrolyzation of the esters of the fatty acids.</p>
          </list-item>
        </list>
        <p>
<bold>Amylase</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Pancreatic amylase&#x000a0;hydrolyzes the alpha 1-4 linkages in the polysaccharides&#x000a0;of three or more linked glucose units.</p>
          </list-item>
          <list-item>
            <p>Starch&#x000a0;is only reduced to a lower compound as alpha 1-6 linkages are not hydrolyzed. Therefore, starch breaks down into dextrins and lower sugars.</p>
          </list-item>
        </list>
        <p>
<bold>Protease</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Pancreatic protease comprises&#x000a0;trypsin and chymotrypsin, which belong to the family of serine proteases.</p>
          </list-item>
          <list-item>
            <p>Trypsin acts on the arginine and lysine residues which are hydrophilic.</p>
          </list-item>
          <list-item>
            <p>Chymotrypsin acts on the hydrophobic residues tryptophan, tyrosine, and phenylalanine.</p>
          </list-item>
          <list-item>
            <p>Both components present a catalytic site formed by the triad of serine, histidine, and aspartate.</p>
          </list-item>
        </list>
        <p>It, therefore, acts as the digestive enzymes inherently secreted by the pancreas in the absence of insufficiency.</p>
        <p>Various factors affect the efficacy of this supplementation, for example:</p>
        <list list-type="bullet">
          <list-item>
            <p>Dose</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal (GI) pH</p>
          </list-item>
          <list-item>
            <p>Size of the micro-spherules</p>
          </list-item>
        </list>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The enzymes are released only if the pH is greater than 5.5.</p>
          </list-item>
          <list-item>
            <p>Some preparations are enteric-coated, which inhibit gastric inactivation during gastric passage and deliver more to the duodenum where it is active.</p>
          </list-item>
          <list-item>
            <p>The GI tract does not absorb the contents in any amounts.</p>
          </list-item>
          <list-item>
            <p>The drug is excreted in the feces.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26556.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Oral Administration</bold>
</p>
        <p>The oral preparation should not be kept in the mouth for prolonged periods as it tends to cause mucosal irritation and stomatitis.</p>
        <p>Various pancrelipase products are not interchangeable; clinicians should not switch between products without verifying dosing.</p>
        <p>For exocrine pancreatic insufficiency, the typical dosing is 500 to 2,500 lipase units with each meal or snack. Different formulations are not dose-transferable, so the prescriber should consult the drug information for each formulation when starting or switching agents.</p>
        <p>
<italic toggle="yes">
<bold>Tablets&#x000a0;</bold>
</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Administered with a meal or immediately before it with sufficient fluids.</p>
          </list-item>
          <list-item>
            <p>The tablet is not to be crushed or chewed.</p>
          </list-item>
          <list-item>
            <p>It should&#x000a0;be taken whole along with a proton pump inhibitor (if not enteric-coated).</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">
<bold>Enteric-Coated Capsules</bold>
</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The drug is administered with a meal or immediately before it with sufficient fluids.</p>
          </list-item>
          <list-item>
            <p>The enteric coating is not to be destroyed;&#x000a0;it should&#x000a0;be consumed whole.</p>
          </list-item>
          <list-item>
            <p>If the patient cannot swallow, the enteric-coated micro-spherules&#x000a0;can be&#x000a0;removed from the capsule and mixed with a small amount of acidic food and administered.</p>
          </list-item>
        </list>
        <p>
<bold>Other Routes of Administration</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Gastrostomy tube:&#x000a0;Factors to be considered include the size of the tube, size of the micro-spherules, feeding schedules, and other concurrent medications to be administered.</p>
          </list-item>
          <list-item>
            <p>Jejunostomy or duodenostomy tube: The enteric coating is destroyed by crushing and then administered after mixing with sodium bicarbonate.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26556.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Mild Adverse Reactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Abdominal pain: Early 3% to 18%</p>
          </list-item>
          <list-item>
            <p>Headache: Early 3% to 15%</p>
          </list-item>
          <list-item>
            <p>Nasal congestion: Early 14%</p>
          </list-item>
          <list-item>
            <p>Otalgia: Early 11%</p>
          </list-item>
          <list-item>
            <p>Infection: Delayed 3% to 11%</p>
          </list-item>
          <list-item>
            <p>Diarrhea: Early 10%</p>
          </list-item>
          <list-item>
            <p>Dyspepsia: Early 10%</p>
          </list-item>
          <list-item>
            <p>Cough:&#x000a0;Delayed 4% to 10%</p>
          </list-item>
          <list-item>
            <p>Flatulence: Early 3% to 9%</p>
          </list-item>
          <list-item>
            <p>Pruritus ani:&#x000a0;Early 7%</p>
          </list-item>
          <list-item>
            <p>Epistaxis: Delayed 7%</p>
          </list-item>
          <list-item>
            <p>Vomiting: Early 6%</p>
          </list-item>
          <list-item>
            <p>Dizziness: Early 4%</p>
          </list-item>
          <list-item>
            <p>Pharyngitis: Delayed 4%</p>
          </list-item>
          <list-item>
            <p>Pruritus: Early 0% to 1%</p>
          </list-item>
          <list-item>
            <p>Urticaria: Early 0% to 1%</p>
          </list-item>
          <list-item>
            <p>Maculopapular rash: Early 0% to 1%&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Nausea: Early incidence not known</p>
          </list-item>
          <list-item>
            <p>Muscle cramps: Delayed incidence not known</p>
          </list-item>
          <list-item>
            <p>Myalgia: Early incidence not known</p>
          </list-item>
          <list-item>
            <p>Lactose intolerance: Early incidence not known</p>
          </list-item>
        </list>
        <p>&#x000a0;<bold>Moderate Adverse Reactions</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>Lymphadenopathy: Delayed 11%</p>
          </list-item>
          <list-item>
            <p>Cholelithiasis: Delayed 7%</p>
          </list-item>
          <list-item>
            <p>Ascites: Delayed 7%</p>
          </list-item>
          <list-item>
            <p>Peripheral edema: Delayed 3%</p>
          </list-item>
          <list-item>
            <p>Anemia: Delayed 3%</p>
          </list-item>
          <list-item>
            <p>Hyperglycemia: Delayed 2%</p>
          </list-item>
          <list-item>
            <p>Hypoglycemia: Early 2%</p>
          </list-item>
          <list-item>
            <p>Constipation: Delayed incidence not known</p>
          </list-item>
          <list-item>
            <p>Stomatitis: Delayed incidence not known</p>
          </list-item>
          <list-item>
            <p>Oral ulceration: Delayed incidence not known</p>
          </list-item>
          <list-item>
            <p>Gastritis: Delayed incidence not known</p>
          </list-item>
          <list-item>
            <p>Esophagitis: Delayed incidence not known</p>
          </list-item>
          <list-item>
            <p>Elevated hepatic enzymes: Delayed incidence not known</p>
          </list-item>
          <list-item>
            <p>Blurred vision: Early incidence not known</p>
          </list-item>
          <list-item>
            <p>Hyperuricemia: Delayed incidence not known</p>
          </list-item>
        </list>
        <p>
<bold>Severe Adverse Reactions&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bronchospasm: Rapid 0% to 1%</p>
          </list-item>
          <list-item>
            <p>Anaphylactoid reactions: Rapid&#x000a0;0% to 1%</p>
          </list-item>
          <list-item>
            <p>Fibrosing colonopathy:&#x000a0;Delayed incidence not known</p>
          </list-item>
          <list-item>
            <p>GI obstruction: Delayed incidence not known</p>
          </list-item>
          <list-item>
            <p>Cholecystitis: Delayed incidence not known</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26556.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Although pancreatic enzyme replacement therapy does have any absolute contraindications per se, a careful analysis of the underlying risks is necessary for the following conditions.<xref ref-type="bibr" rid="article-26556.r10">[10]</xref><xref ref-type="bibr" rid="article-26556.r11">[11]</xref></p>
        <p>
<bold>Diabetes Mellitus&#x000a0;</bold>
</p>
        <p>Pancrelipase affects glycemic control. Hence patients diagnosed with diabetes mellitus or patients at risk for abnormal blood sugar levels should have strict glucose monitoring while taking pancrelipase.</p>
        <p>
<bold>Immunocompromised States</bold>
</p>
        <p>Pancrelipase derives from the pancreatic tissue of swine. Although rigorous measures are in place to ensure no risk of transmitting viral infections to the patient, there is a theoretical risk from unknown viruses in the swine. Therefore, patients who are immunocompromised/immunodeficient are at an increased risk of contracting infections while on this medication.</p>
        <p>
<bold>Hyperuricemia and Renal Impairment</bold>
</p>
        <p>As this medication is porcine-derived, it contains certain nucleic acids that tend to&#x000a0;increase blood uric acid levels. Patients with pre-existing hyperuricemia or gout and patients with decreased renal functions are to be closely monitored when on the drug.</p>
        <p>
<bold>Dysphagia</bold>
</p>
        <p>As mentioned earlier, patients with a tendency to retain the contents of the medications higher up&#x000a0;in the gastrointestinal tract may develop mucosal irritation and mucositis. Care is necessary while administering the drug to patients with esophageal strictures and dysphagia.</p>
        <p>
<bold>Meconium Ileus, Intestinal Obstruction, Inflammatory Bowel Disease, and Surgery</bold>
</p>
        <p>Patients younger than 12 years of age, patients who have taken more than 6000 lipase units/kg per meal for more than six months,&#x000a0;or patients&#x000a0;with a history of meconium ileus, intestinal obstruction, inflammatory bowel disease, or abdominal surgery have the highest risk for developing fibrosing colonopathy. It is a rare but serious complication of enzyme replacement characterized by GI obstruction, bloody diarrhea, abdominal pain, and poor weight gain.</p>
        <p>Therefore, it has been recommended by the Cystic Fibrosis Foundation Consensus Conference Guidelines that the efficacy of lipase supplementation more than 2500 units/kg per meal be confirmed by a 3-day fecal-fat measure that indicated an increased fat absorption coefficient. The dose is then to be adjusted accordingly.</p>
        <p>
<bold>Pregnancy</bold>
</p>
        <p>There are not adequate numbers of human and animal reproduction studies for this drug. Therefore, its use in pregnancy should be limited to those patients with exocrine pancreatic insufficiency who have inadequate maternal weight gain; this may adversely affect fetal growth, and hence supplementation is justified.</p>
        <p>
<bold>Breastfeeding</bold>
</p>
        <p>All breastfeeding mothers should contact their healthcare provider before taking pancrelipase. Some proteins present in the product may undergo systemic absorption along with the dietary protein. There is no data available about the uptake of these substances into breast milk; it is only recommended when it is necessary to support the mother's nutritional status.</p>
        <p>
<bold>Porcine Protein Sensitivity</bold>
</p>
        <p>There are reports of anaphylactic reactions, hives, asthma, urticaria,&#x000a0;and&#x000a0;pruritus in patients with prior hypersensitivity to porcine protein. Caution is necessary for all these patients.</p>
      </sec>
      <sec id="article-26556.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The maximum dosage of pancrelipase&#x000a0;is&#x000a0;as follows:</p>
        <p>
<bold>Adults</bold>
</p>
        <p>The recommendation is a maximum of 10,000 lipase units per kg per day orally (PO) or less than 4,000 lipase units per gram of dietary fat per day.</p>
        <p>
<bold>Geriatric</bold>
</p>
        <p>The recommendation is a maximum of 10,000 lipase units per kg per day PO or less than 4,000 lipase units per gram of dietary fat per day.</p>
        <p>
<bold>Adolescents</bold>
</p>
        <p>The recommendation is a maximum of 10,000 lipase units per kg per day PO or less than 4,000 lipase units per gram of dietary fat per day.</p>
        <p>But at no time should the maximum dosage exceed 2,500 lipase units per kg per meal.</p>
        <p>
<bold>Infant Dosage</bold>
</p>
        <p>Infant dosages are product-specific. But the maximum dosage is not to exceed 4,000 lipase units per gram of ingested fat per day or 10,000 lipase units/kg per day.</p>
        <p>
<bold>Neonates</bold>
</p>
        <p>Neonatal dosages are product-specific.</p>
        <p>There are no dosage adjustments required for renal and hepatic impairment.</p>
        <p>
<bold>Drug Interactions That May Require Dosage Adjustments</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><italic toggle="yes">Antacids:</italic>&#x000a0;The efficacy of gastrointestinal enzyme replacement therapy becomes reduced in the presence of antacids. Calcium and magnesium cations exert their effect by forming poorly soluble calcium and magnesium soaps and precipitation of glycine-conjugated bile salts based on in-vitro studies.</p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Alpha-glucosidase inhibitors:</italic>&#x000a0;Concurrent administration of gastrointestinal enzyme replacement therapy reduces the efficacy of alpha-glucosidase inhibitors. Ideally, the administration of each drug should be at different times. But this may not be possible, considering both drugs are to b administered around mealtime.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26556.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Chronic, high-dose pancreatic enzyme replacement can cause colonic strictures and fibrosing colonopathy.<xref ref-type="bibr" rid="article-26556.r12">[12]</xref>&#x000a0;Fibrosing colonopathy is a condition in which there is a narrowing of the lumen of a long segment of the colon. This condition occurs due to submucosal widening due to the deposition of mature collagen. Most commonly seen in children with cystic fibrosis as they require long-term high-dose pancreatic enzyme replacement.</p>
      </sec>
      <sec id="article-26556.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The administration of pancreatic enzyme replacement therapy requires the efficient functioning of an interprofessional team to ensure the best benefit to the patient. The team usually comprises a clinician, nurse practitioner, pharmacist, nutritionist/dietician, physiotherapist, and nurses. The primary provider may additionally involve physicians from oncology, gastroenterology, surgery, pulmonology, or pediatrics, depending on the etiology of the enzyme insufficiency. The primary care provider is&#x000a0;involved in the diagnosis of insufficiency.&#x000a0;The PCP is then responsible for managing the symptoms, deciding the supplementation requirements of the patients, monitoring progress, and managing any side effects that might result thereof. Nurse practitioners are required to alternate with physicians to monitor patient progress with the medications. Pharmacists should provide patients and families with information on the drug, side effects, precautions, and contraindications. They are also responsible for dose alterations as the case demands. Dieticians and nutritionists should assess the patient's nutritional status and determine the calorie requirement. They are also&#x000a0;required to determine the need for vitamin supplements, growth hormone, and appetite stimulants. Physiotherapists are required to help with the ambulation of patients with chronic illnesses like pancreatic cancer and chronic pancreatitis. They should also be on board when dealing with cases of cystic fibrosis. Nurses are an integral part of the team, especially in the inpatient setting, to ensure that all orders are executed. They are also an essential link in communication between physicians and patients. No evidence is available for the effectiveness of an interprofessional approach to pancreatic enzyme replacement therapy.</p>
        <p>Various studies have shown the benefit of involving an interprofessional team for patients with cystic fibrosis.<xref ref-type="bibr" rid="article-26556.r13">[13]</xref></p>
      </sec>
      <sec id="article-26556.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26556&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26556">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/26556/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=26556">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-26556.s11">
        <title>References</title>
        <ref id="article-26556.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Durie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Baillargeon</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Bouchard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Donnellan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zepeda-Gomez</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Teshima</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of pancreatic exocrine insufficiency (PEI) in primary care: consensus guidance of a Canadian expert panel.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-33</page-range>
            <pub-id pub-id-type="pmid">28985688</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26556.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Min</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bocelli</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kheder</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vaze</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wassef</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Exocrine Pancreatic Insufficiency and Malnutrition in Chronic Pancreatitis: Identification, Treatment, and Consequences.</article-title>
            <source>Pancreas</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>47</volume>
            <issue>8</issue>
            <fpage>1015</fpage>
            <page-range>1015-1018</page-range>
            <pub-id pub-id-type="pmid">30074926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26556.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saito</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Isayama</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hirano</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ishigaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hakuta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Takeda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Umefune</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Akiyama</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Takagi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takahara</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hamada</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Uchino</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mizuno</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mouri</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Yagioka</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kogure</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Togawa</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Matsubara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Koike</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>A Multicenter Open-Label Randomized Controlled Trial of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer.</article-title>
            <source>Pancreas</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>47</volume>
            <issue>7</issue>
            <fpage>800</fpage>
            <page-range>800-806</page-range>
            <pub-id pub-id-type="pmid">29851751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26556.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dom&#x000ed;nguez-Mu&#x000f1;oz</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Pancreatic enzyme replacement therapy: exocrine pancreatic insufficiency after gastrointestinal surgery.</article-title>
            <source>HPB (Oxford)</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>11 Suppl 3</volume>
            <issue>Suppl 3</issue>
            <fpage>3</fpage>
            <page-range>3-6</page-range>
            <pub-id pub-id-type="pmid">20495625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26556.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Antonini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Crippa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Falconi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Macarri</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pezzilli</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Pancreatic enzyme replacement therapy after gastric resection: An update.</article-title>
            <source>Dig Liver Dis</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>50</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-5</page-range>
            <pub-id pub-id-type="pmid">29170072</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26556.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giguere-Rich</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mathew</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Autore</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Guill</surname>
                <given-names>MF</given-names>
              </name>
            </person-group>
            <article-title>Use of an In-line Digestive Cartridge With Enteral Nutrition Improves the Weight Trajectory of 2 Children With Cystic Fibrosis Complicated by Another Medical Diagnosis.</article-title>
            <source>Nutr Clin Pract</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>33</volume>
            <issue>2</issue>
            <fpage>286</fpage>
            <page-range>286-294</page-range>
            <pub-id pub-id-type="pmid">29658186</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26556.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stumpf</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Kurian</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Vuong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kraft</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of a Creon delayed-release pancreatic enzyme protocol for clearing occluded enteral feeding tubes.</article-title>
            <source>Ann Pharmacother</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>48</volume>
            <issue>4</issue>
            <fpage>483</fpage>
            <page-range>483-7</page-range>
            <pub-id pub-id-type="pmid">24436458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26556.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>JAKOVCIC</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>HSIA</surname>
                <given-names>DY</given-names>
              </name>
            </person-group>
            <article-title>Studies on mechanism for decreased lipoprotein lipase in cystic fibrosis of the pancrease.</article-title>
            <source>J Pediatr</source>
            <year>1963</year>
            <month>Jan</month>
            <volume>62</volume>
            <fpage>25</fpage>
            <page-range>25-30</page-range>
            <pub-id pub-id-type="pmid">13964519</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26556.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferrone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Raimondo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Scolapio</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Pancreatic enzyme pharmacotherapy.</article-title>
            <source>Pharmacotherapy</source>
            <year>2007</year>
            <month>Jun</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>910</fpage>
            <page-range>910-20</page-range>
            <pub-id pub-id-type="pmid">17542772</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26556.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lindkvist</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of pancreatic exocrine insufficiency.</article-title>
            <source>World J Gastroenterol</source>
            <year>2013</year>
            <month>Nov</month>
            <day>14</day>
            <volume>19</volume>
            <issue>42</issue>
            <fpage>7258</fpage>
            <page-range>7258-66</page-range>
            <pub-id pub-id-type="pmid">24259956</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26556.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakajima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Oshida</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Muneyuki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kakei</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pancrelipase: an evidence-based review of its use for treating pancreatic exocrine insufficiency.</article-title>
            <source>Core Evid</source>
            <year>2012</year>
            <volume>7</volume>
            <fpage>77</fpage>
            <page-range>77-91</page-range>
            <pub-id pub-id-type="pmid">22936895</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26556.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dodge</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Pancreatic enzymes and Fibrosing Colonopathy.</article-title>
            <source>J Cyst Fibros</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>153</fpage>
            <pub-id pub-id-type="pmid">25242743</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26556.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Collins</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Nutritional management of cystic fibrosis - an update for the 21st century.</article-title>
            <source>Paediatr Respir Rev</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>26</volume>
            <fpage>4</fpage>
            <page-range>4-6</page-range>
            <pub-id pub-id-type="pmid">28420572</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
